Product Pathways - Apoptosis
Survivin Blocking Peptide #1037
|Item#||Description||List Price||New Lab Price||Qty|
|Item#||Description||List Price||Web Price||Qty|
This peptide is used to specifically block Survivin (71G4) Rabbit mAb #2808 reactivity.
The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks Survivin (71G4) Rabbit mAb #2808 by immunohistochemistry.
Directions For Use
Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols. For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 µl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the relevant product data sheet.
Survivin is a 16 kDa anti-apoptotic protein highly expressed during fetal development and cancer cell malignancy (1). Survivin binds and inhibits caspase-3, controlling the checkpoint in the G2/M-phase of the cell cycle by inhibiting apoptosis and promoting cell division (2,3). This regulatory process requires the phosphorylation of survivin at Thr34 by p34 cdc2 kinase (4). Gene targeting using a Thr34 phosphorylation-defective survivin mutant, as well as antisense survivin, have been shown to inhibit tumor growth (5,6).
- Reed, J.C. and Reed, S.I. (1999) Nature Cell Biol. 1, 199-200.
- Li, F. et al. (1998) Nature 396, 580-584.
- Li, F. et al. (1999) Nat. Cell Biol. 1, 461-466.
- O'Connor, D.S. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 13103-13107.
- Olie, R.A. et al. (2000) Cancer Res. 60, 2805-2809.
- Grossman, D. et al. (2001) Proc. Natl. Acad. Sci. USA 98, 635-640.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.